John Zuris

Company: Editas Medicine

Job title: Director, Editing Technologies

Seminars:

Presenting SLEEK: a Highly Efficient Knock-In Technology for NextGeneration Cellular Medicines 8:50 am

Illuminating a greater than 90% knock-in efficiency across clinically relevant cell types to ensure guaranteed robust expression of single and multiple transgene cargos Demonstrating equal efficiency with both viral and non-viral DNA donor templates to provide a manufacturing advantage for enhanced scalability Weaponizing the next generation of iPSC-derived NK cells (iNKs) with robust tumor killing…Read more

day: Day Two